Pages that link to "Q28239840"

The following pages link to Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study (Q28239840):

Displaying 35 items.

• The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments (Q26739291) (← links)
• Mechanism-Oriented Therapy of Irritable Bowel Syndrome (Q26747875) (← links)
• Gut microbiota as potential orchestrators of irritable bowel syndrome (Q28085584) (← links)
• What is the therapeutic mechanism of the probiotics in irritable bowel syndrome patients with visceral hypersensitivity? (Q34377233) (← links)
• Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. (Q35586987) (← links)
• Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome (Q35867820) (← links)
• Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis (Q36050769) (← links)
• Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? (Q36211712) (← links)
• Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome (Q36347301) (← links)
• The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease (Q36751990) (← links)
• Irritable bowel syndrome symptom severity improves equally with probiotic and placebo (Q37538949) (← links)
• Drug discovery approaches to irritable bowel syndrome (Q38550878) (← links)
• British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). (Q38855986) (← links)
• British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). (Q38858071) (← links)
• Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome (Q41172853) (← links)
• Editorial: The importance of systematic reviews and meta-analyses of probiotics and prebiotics. (Q45978689) (← links)
• The Role of the Gastrointestinal Microbiota in Visceral Pain (Q46438777) (← links)
• Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation (Q47164662) (← links)
• The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome (Q49653059) (← links)
• A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). (Q49721831) (← links)
• Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus (Q49822026) (← links)
• The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial (Q50300062) (← links)
• Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. (Q52672657) (← links)
• A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. (Q54087826) (← links)
• A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. (Q55063629) (← links)
• Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives (Q57489996) (← links)
• Reduction in butyrate-producing Lachnospiraceae contributes to stress-induced visceral hypersensitivity in rats (Q58607516) (← links)
• The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation (Q59807725) (← links)
• A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. (Q64994055) (← links)
• Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells (Q90427027) (← links)
• Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis (Q90449039) (← links)
• Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik (Q90729716) (← links)
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) (Q91792226) (← links)
• Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis (Q92132034) (← links)
• Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review (Q93080867) (← links)